Cargando…

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin

BACKGROUND: The FAST was a factorial trial in first-line treatment of advanced non-small-cell lung cancer (NSCLC), addressing the role of replacing cisplatin with a non-platinum agent. The prognostic and predictive effect of ERCC1/BRCA1 expression and ERCC1/XPD/XRCC1–3 gene polymorphisms on outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tiseo, M, Bordi, P, Bortesi, B, Boni, L, Boni, C, Baldini, E, Grossi, F, Recchia, F, Zanelli, F, Fontanini, G, Naldi, N, Campanini, N, Azzoni, C, Bordi, C, Ardizzoni, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669730/ https://www.ncbi.nlm.nih.gov/pubmed/23549037 http://dx.doi.org/10.1038/bjc.2013.127

Ejemplares similares

Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST)
por: Boni, C, et al.
Publicado: (2012)

Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy
por: Negri, F V, et al.
Publicado: (2008)

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
por: Tiseo, M, et al.
Publicado: (2010)

CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients
por: Park, S R, et al.
Publicado: (2011)

Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC)
por: Baldini, E, et al.
Publicado: (2001)

ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
por: Jun, H J, et al.
Publicado: (2008)

Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: a case report
por: Minari, Roberta, et al.
Publicado: (2020)

Pathogenesis of ECL cell tumors in humans.
por: Bordi, C., et al.
Publicado: (1998)

Mapping loss of heterozygosity in normal human breast cells from BRCA1/2 carriers
por: Clarke, C L, et al.
Publicado: (2006)

ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen
por: Wei, J, et al.
Publicado: (2008)

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
por: Basso, M, et al.
Publicado: (2013)

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer
por: Matsubara, J, et al.
Publicado: (2008)

Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review
por: Militello, Anna Maria, et al.
Publicado: (2019)

MiR-204 inhibits human NSCLC metastasis through suppression of NUAK1
por: Shi, L, et al.
Publicado: (2014)

Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis
por: Di Federico, Alessandro, et al.
Publicado: (2021)

Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
por: Osorio, A, et al.
Publicado: (2009)

Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC)
por: Rocks, N, et al.
Publicado: (2006)

Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report
por: Bordi, Paola, et al.
Publicado: (2016)

Evaluation of models to predict BRCA germline mutations
por: Kang, H H, et al.
Publicado: (2006)

Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer
por: Santivasi, W L, et al.
Publicado: (2015)

The Expression of ERCC1, RRM1, and BRCA1 in Breast Cancer According to the Immunohistochemical Phenotypes
por: Kim, Dokyung, et al.
Publicado: (2011)

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
por: Verzè, Michela, et al.
Publicado: (2021)

The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC
por: Nygaard, A D, et al.
Publicado: (2014)

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
por: Song, Wenhui, et al.
Publicado: (2016)

Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients
por: Ruiz, M I Galleges, et al.
Publicado: (2009)

Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs
por: Leonetti, Alessandro, et al.
Publicado: (2021)

Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
por: Pellegrino, B., et al.
Publicado: (2020)

Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2011)

EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice
por: Gahr, S, et al.
Publicado: (2013)

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
por: Facchinetti, Francesco, et al.
Publicado: (2018)

hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma
por: Lastraioli, E, et al.
Publicado: (2015)

DNA repair capacity as a possible biomarker of breast cancer risk in female BRCA1 mutation carriers
por: Kotsopoulos, J, et al.
Publicado: (2007)

The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC
por: Cai, Yang, et al.
Publicado: (2015)

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
por: Schirripa, M, et al.
Publicado: (2015)

BRCA1 tumours correlate with a HIF-1α phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression
por: Yan, M, et al.
Publicado: (2009)

Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer
por: Boldrini, L, et al.
Publicado: (2005)

Relevance of ERCC1, RRM1 and BRCA1 in surgically treated non-small cell lung cancer patients
por: Pesta, Martin, et al.
Publicado: (2014)

The glycosphingolipid P(1) is an ovarian cancer-associated carbohydrate antigen involved in migration
por: Jacob, F, et al.
Publicado: (2014)

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel
por: Wang, Lifeng, et al.
Publicado: (2008)

BRCA1 and ERCC1 mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer
por: Yuanming, Lu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ksvk1mds9234os177miuapgbg8